InvestorsHub Logo
Followers 229
Posts 22046
Boards Moderated 4
Alias Born 09/16/2011

Re: surf1944 post# 72

Saturday, 12/07/2013 6:38:44 AM

Saturday, December 07, 2013 6:38:44 AM

Post# of 83
Auxilium Pharma confirms FDA approval for XIAFLEX for the treatment of Peyronie's disease

1:30 PM ET 12/6/13 | Briefing.com

Co announced that the FDA has approved XIAFLEX (collagenase clostridium histolyticum, or CCH), an in-office, biologic for the treatment of Peyronie's disease (PD). XIAFLEX is the first and only FDA-approved treatment proven effective for PD in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy. XIAFLEX has already been approved in the U.S., EU, Canada and Australia for the treatment of adult Dupuytren's contracture (DC) patients with a palpable cord. XIAFLEX for the treatment of DC is marketed under the trade name XIAPEX in the EU.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.